Published in Hepatology on October 01, 2004
Does an index composed of clinical data reflect effects of inflammation, coagulation, and monocyte activation on mortality among those aging with HIV? Clin Infect Dis (2012) 2.45
Alcohol and hepatitis C virus--interactions in immune dysfunctions and liver damage. Alcohol Clin Exp Res (2010) 1.77
Hepatitis C virus clearance, reinfection, and persistence, with insights from studies of injecting drug users: towards a vaccine. Lancet Infect Dis (2012) 1.66
Higher clearance of hepatitis C virus infection in females compared with males. Gut (2006) 1.57
Factors associated with spontaneous clearance of hepatitis C virus among illicit drug users. Can J Gastroenterol (2007) 1.44
Impaired hepatitis C virus-specific T cell responses and recurrent hepatitis C virus in HIV coinfection. PLoS Med (2006) 1.36
Correlates of spontaneous clearance of hepatitis C virus among people with hemophilia. Blood (2005) 1.28
Factors associated with hepatitis C viremia in a large cohort of HIV-infected and -uninfected women. J Clin Virol (2008) 1.15
The role of gender on clearance of hepatitis C virus: a different story in an area endemic for hepatitis B and C. Gut (2007) 1.10
Spontaneous elimination of hepatitis C virus infection: a retrospective study on demographic, clinical, and serological correlates. World J Gastroenterol (2007) 0.91
The impact of illicit drug use on spontaneous hepatitis C clearance: experience from a large cohort population study. PLoS One (2011) 0.87
Influence of healthcare-associated factors on the efficacy of hepatitis C therapy. ScientificWorldJournal (2012) 0.86
Alcohol use disorder and its impact on chronic hepatitis C virus and human immunodeficiency virus infections. World J Hepatol (2016) 0.85
Injection Drug Use and Hepatitis C as Risk Factors for Mortality in HIV-Infected Individuals: The Antiretroviral Therapy Cohort Collaboration. J Acquir Immune Defic Syndr (2015) 0.85
Molecular mechanisms involved in the interaction effects of alcohol and hepatitis C virus in liver cirrhosis. Mol Med (2010) 0.83
Update on Alcohol and Viral Hepatitis. J Clin Transl Hepatol (2014) 0.81
A longitudinal study of hepatitis C virus testing and infection status notification on behaviour change in people who inject drugs. J Epidemiol Community Health (2015) 0.78
Predictors of alcohol use among rural drug users after disclosure of hepatitis C virus status. J Stud Alcohol Drugs (2013) 0.77
Diversity of killer cell immunoglobulin-like receptor (KIR) genotypes and KIR2DL2/3 variants in HCV treatment outcome. PLoS One (2014) 0.77
Factors associated with spontaneous clearance of hepatitis C virus in Chinese population. Biomed Res Int (2014) 0.77
Ethnicity and spontaneous clearance of hepatitis C in HIV-HCV coinfected patients. Can J Infect Dis Med Microbiol (2008) 0.76
Evaluation of the significance of pretreatment liver biopsy and baseline mental health disorder diagnosis on hepatitis C treatment completion rates at a veterans affairs medical center. Hepat Res Treat (2013) 0.75
Opportunities in proteomics to understand hepatitis C and HIV coinfection. Future Virol (2012) 0.75
The effects of alcohol on spontaneous clearance of acute hepatitis C virus infection in females versus males. Drug Alcohol Depend (2016) 0.75
Hepatitis infection in the treatment of opioid dependence and abuse. Subst Abuse (2008) 0.75
Hepatitis C cross-genotype immunity and implications for vaccine development. Sci Rep (2017) 0.75
Peginterferon alfa-2a plus ribavirin for chronic hepatitis C virus infection. N Engl J Med (2002) 36.55
Boceprevir for untreated chronic HCV genotype 1 infection. N Engl J Med (2011) 19.01
Linking long-term dietary patterns with gut microbial enterotypes. Science (2011) 17.30
Telaprevir for previously untreated chronic hepatitis C virus infection. N Engl J Med (2011) 16.93
Sofosbuvir for previously untreated chronic hepatitis C infection. N Engl J Med (2013) 13.30
Long-term proton pump inhibitor therapy and risk of hip fracture. JAMA (2006) 9.53
Ledipasvir and sofosbuvir for previously treated HCV genotype 1 infection. N Engl J Med (2014) 9.45
Intestinal microbiota metabolism of L-carnitine, a nutrient in red meat, promotes atherosclerosis. Nat Med (2013) 9.44
Daclatasvir plus sofosbuvir for previously treated or untreated chronic HCV infection. N Engl J Med (2014) 9.25
Sampling error and intraobserver variation in liver biopsy in patients with chronic HCV infection. Am J Gastroenterol (2002) 8.21
Ledipasvir and sofosbuvir for 8 or 12 weeks for chronic HCV without cirrhosis. N Engl J Med (2014) 7.73
The association between hepatitis C infection and survival after orthotopic liver transplantation. Gastroenterology (2002) 4.98
Sampling and pyrosequencing methods for characterizing bacterial communities in the human gut using 16S sequence tags. BMC Microbiol (2010) 4.97
ABT-450/r-ombitasvir and dasabuvir with or without ribavirin for HCV. N Engl J Med (2014) 4.90
Diagnosis and treatment of hepatocellular carcinoma. Gastroenterology (2008) 4.73
Serum lactate is associated with mortality in severe sepsis independent of organ failure and shock. Crit Care Med (2009) 4.56
Alpha-fetoprotein, des-gamma carboxyprothrombin, and lectin-bound alpha-fetoprotein in early hepatocellular carcinoma. Gastroenterology (2009) 4.50
Innate lymphoid cells promote anatomical containment of lymphoid-resident commensal bacteria. Science (2012) 4.20
Early identification of HCV genotype 1 patients responding to 24 weeks peginterferon alpha-2a (40 kd)/ribavirin therapy. Hepatology (2006) 3.92
Initiation of tumor necrosis factor-α antagonists and the risk of hospitalization for infection in patients with autoimmune diseases. JAMA (2011) 3.58
Insulin therapy and colorectal cancer risk among type 2 diabetes mellitus patients. Gastroenterology (2004) 3.57
Peginterferon alfa-2a (40 kd) and ribavirin for black American patients with chronic HCV genotype 1. Hepatology (2004) 3.47
Rare birds in North America: acute hepatitis C cohorts. Gastroenterology (2008) 3.45
Re-treatment of patients with chronic hepatitis C who do not respond to peginterferon-alpha2b: a randomized trial. Ann Intern Med (2009) 3.41
Clinical risk factors for primary graft dysfunction after lung transplantation. Am J Respir Crit Care Med (2013) 3.38
The human gut virome: inter-individual variation and dynamic response to diet. Genome Res (2011) 3.32
Sofosbuvir in combination with peginterferon alfa-2a and ribavirin for non-cirrhotic, treatment-naive patients with genotypes 1, 2, and 3 hepatitis C infection: a randomised, double-blind, phase 2 trial. Lancet Infect Dis (2013) 3.30
Factors associated with nonadherence to early goal-directed therapy in the ED. Chest (2010) 3.23
Sofosbuvir and Velpatasvir for HCV in Patients with Decompensated Cirrhosis. N Engl J Med (2015) 3.13
Prevalence and treatment of psoriasis in the United Kingdom: a population-based study. Arch Dermatol (2005) 3.11
Predicting sustained virological responses in chronic hepatitis C patients treated with peginterferon alfa-2a (40 KD)/ribavirin. J Hepatol (2005) 3.10
Prospective multicenter study of eligibility for antiviral therapy among 4,084 U.S. veterans with chronic hepatitis C virus infection. Am J Gastroenterol (2005) 3.09
Efficacy of anti-tumor necrosis factor therapy in patients with ulcerative colitis. Am J Gastroenterol (2002) 3.01
Functional restoration of HCV-specific CD8 T cells by PD-1 blockade is defined by PD-1 expression and compartmentalization. Gastroenterology (2008) 2.95
Mortality associated with medical therapy versus elective colectomy in ulcerative colitis: a cohort study. Ann Intern Med (2014) 2.73
The adult respiratory distress syndrome cognitive outcomes study: long-term neuropsychological function in survivors of acute lung injury. Am J Respir Crit Care Med (2012) 2.72
Synergistic reversal of intrahepatic HCV-specific CD8 T cell exhaustion by combined PD-1/CTLA-4 blockade. PLoS Pathog (2009) 2.57
Rapid evolution of the human gut virome. Proc Natl Acad Sci U S A (2013) 2.53
Association between vaccination for herpes zoster and risk of herpes zoster infection among older patients with selected immune-mediated diseases. JAMA (2012) 2.51
Hepatitis C virus transmission bottlenecks analyzed by deep sequencing. J Virol (2010) 2.45
Suppression of HCV-specific T cells without differential hierarchy demonstrated ex vivo in persistent HCV infection. Hepatology (2003) 2.45
First phase viral kinetic parameters as predictors of treatment response and their influence on the second phase viral decline. J Viral Hepat (2002) 2.43
Use of abdominopelvic computed tomography in emergency departments and rates of urgent diagnoses in Crohn's disease. Clin Gastroenterol Hepatol (2011) 2.40
The risk of mortality in patients with psoriasis: results from a population-based study. Arch Dermatol (2007) 2.32
Randomized, double-blind, controlled study of glycerol phenylbutyrate in hepatic encephalopathy. Hepatology (2014) 2.28
Incidence and mortality of colorectal adenocarcinoma in persons with inflammatory bowel disease from 1998 to 2010. Gastroenterology (2012) 2.26
Development of an internet-based cohort of patients with inflammatory bowel diseases (CCFA Partners): methodology and initial results. Inflamm Bowel Dis (2012) 2.23
Peginterferon alfa-2a (40 kilodaltons) and ribavirin in patients with chronic hepatitis C and normal aminotransferase levels. Gastroenterology (2004) 2.17
Managed problem solving for antiretroviral therapy adherence: a randomized trial. JAMA Intern Med (2013) 2.16
Incidence and risk factors for herpes zoster among patients with inflammatory bowel disease. Clin Gastroenterol Hepatol (2006) 2.16
Increased risk for demyelinating diseases in patients with inflammatory bowel disease. Gastroenterology (2005) 2.15
Rates of malignancy associated with juvenile idiopathic arthritis and its treatment. Arthritis Rheum (2012) 2.15
Association of 6-thioguanine nucleotide levels and inflammatory bowel disease activity: a meta-analysis. Gastroenterology (2006) 2.14
Initiation of anti-TNF therapy and the risk of optic neuritis: from the safety assessment of biologic ThERapy (SABER) Study. Am J Ophthalmol (2012) 2.14
Grazoprevir-Elbasvir Combination Therapy for Treatment-Naive Cirrhotic and Noncirrhotic Patients With Chronic Hepatitis C Virus Genotype 1, 4, or 6 Infection: A Randomized Trial. Ann Intern Med (2015) 2.13
AGA medical position statement on the diagnosis and management of colorectal neoplasia in inflammatory bowel disease. Gastroenterology (2010) 2.09
Hepatitis C virus treatment-related anemia is associated with higher sustained virologic response rate. Gastroenterology (2010) 2.06
Discordant role of CD4 T-cell response relative to neutralizing antibody and CD8 T-cell responses in acute hepatitis C. Gastroenterology (2006) 2.05
An optimized patient-reported ulcerative colitis disease activity measure derived from the Mayo score and the simple clinical colitis activity index. Inflamm Bowel Dis (2014) 2.05
Concordance of sustained virological response 4, 12, and 24 weeks post-treatment with sofosbuvir-containing regimens for hepatitis C virus. Hepatology (2014) 2.04
Risks of herpes zoster in patients with rheumatoid arthritis according to biologic disease-modifying therapy. Arthritis Care Res (Hoboken) (2015) 2.03
Framing Financial Incentives to Increase Physical Activity Among Overweight and Obese Adults: A Randomized, Controlled Trial. Ann Intern Med (2016) 1.96
Liver transplantation for hepatocellular carcinoma validation of present selection criteria in predicting outcome. Liver Transpl (2004) 1.95
Corticosteroids and immunomodulators: postoperative infectious complication risk in inflammatory bowel disease patients. Gastroenterology (2003) 1.94
Trends in the use of biologic agents among rheumatoid arthritis patients enrolled in the US medicare program. Arthritis Care Res (Hoboken) (2013) 1.92
Risk of kidney injury following oral phosphosoda bowel preparations. J Am Soc Nephrol (2007) 1.89
Renal function after orthotopic liver transplantation is predicted by duration of pretransplantation creatinine elevation. Liver Transpl (2005) 1.87
The North American Study for the Treatment of Refractory Ascites. Gastroenterology (2003) 1.87
Liver injury from herbals and dietary supplements in the U.S. Drug-Induced Liver Injury Network. Hepatology (2014) 1.83
Cohort study of pioglitazone and cancer incidence in patients with diabetes. Diabetes Care (2011) 1.83
Latent class analysis identifies distinct phenotypes of primary graft dysfunction after lung transplantation. Chest (2013) 1.79
Validity of diagnostic codes and liver-related laboratory abnormalities to identify hepatic decompensation events in the Veterans Aging Cohort Study. Pharmacoepidemiol Drug Saf (2011) 1.76
Time trends in therapies and outcomes for adult inflammatory bowel disease, Northern California, 1998-2005. Gastroenterology (2009) 1.74
Second infections independently increase mortality in hospitalized patients with cirrhosis: the North American consortium for the study of end-stage liver disease (NACSELD) experience. Hepatology (2012) 1.74
Lack of benefit of pre-transplant locoregional hepatic therapy for hepatocellular cancer in the current MELD era. Liver Transpl (2006) 1.72
Prevalence and significance of occult hepatitis B in a liver transplant population with chronic hepatitis C. Liver Transpl (2008) 1.72
Incidence and prevalence of inflammatory bowel disease in a Northern California managed care organization, 1996-2002. Am J Gastroenterol (2008) 1.72
Longitudinal trends in antimicrobial susceptibilities across long-term-care facilities: emergence of fluoroquinolone resistance. Infect Control Hosp Epidemiol (2005) 1.71
Association between longer therapy with thiazolidinediones and risk of bladder cancer: a cohort study. J Natl Cancer Inst (2012) 1.69
Endoscopic management of biliary complications after adult living donor liver transplantation. Am J Gastroenterol (2004) 1.68
Cancer incidence in The Health Improvement Network. Pharmacoepidemiol Drug Saf (2009) 1.65
Archaea and fungi of the human gut microbiome: correlations with diet and bacterial residents. PLoS One (2013) 1.64
Hepatic decompensation in antiretroviral-treated patients co-infected with HIV and hepatitis C virus compared with hepatitis C virus-monoinfected patients: a cohort study. Ann Intern Med (2014) 1.64
Identification and in vitro expansion of functional antigen-specific CD25+ FoxP3+ regulatory T cells in hepatitis C virus infection. J Virol (2008) 1.63
Effects of ribavirin dose reduction vs erythropoietin for boceprevir-related anemia in patients with chronic hepatitis C virus genotype 1 infection--a randomized trial. Gastroenterology (2013) 1.63
Intervention to influence behaviors linked to risk of chronic diseases: a multisite randomized controlled trial with African-American HIV-serodiscordant heterosexual couples. Arch Intern Med (2011) 1.62
Validity of The Health Improvement Network (THIN) for epidemiologic studies of hepatitis C virus infection. Pharmacoepidemiol Drug Saf (2009) 1.61
Immune dysfunction and infections in patients with cirrhosis. Clin Gastroenterol Hepatol (2011) 1.61
Comparison of clinical outcomes in chronic hepatitis B liver transplant candidates with and without hepatocellular carcinoma. Liver Transpl (2007) 1.61
School-based randomized controlled trial of an HIV/STD risk-reduction intervention for South African adolescents. Arch Pediatr Adolesc Med (2010) 1.59
Hypervariable loci in the human gut virome. Proc Natl Acad Sci U S A (2012) 1.58
Transplantation: impact of pretransplant renal insufficiency. Liver Transpl (2008) 1.58
Outcomes in hepatitis C virus-infected recipients of living donor vs. deceased donor liver transplantation. Liver Transpl (2007) 1.58
National Institute of Mental Health Multisite Eban HIV/STD Prevention Intervention for African American HIV Serodiscordant Couples: a cluster randomized trial. Arch Intern Med (2010) 1.57
Comparing the safety, tolerability and quality of life in patients with chronic hepatitis B vs chronic hepatitis C treated with peginterferon alpha-2a. Liver Int (2008) 1.56
Risk of waitlist mortality in patients with primary sclerosing cholangitis and bacterial cholangitis. Liver Transpl (2013) 1.52
A meta-analysis of the placebo rates of remission and response in clinical trials of active Crohn's disease. Gastroenterology (2004) 1.51